Cargando…
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remd...
Autores principales: | Pruijssers, Andrea J., George, Amelia S., Schäfer, Alexandra, Leist, Sarah R., Gralinksi, Lisa E., Dinnon, Kenneth H., Yount, Boyd L., Agostini, Maria L., Stevens, Laura J., Chappell, James D., Lu, Xiaotao, Hughes, Tia M., Gully, Kendra, Martinez, David R., Brown, Ariane J., Graham, Rachel L., Perry, Jason K., Du Pont, Venice, Pitts, Jared, Ma, Bin, Babusis, Darius, Murakami, Eisuke, Feng, Joy Y., Bilello, John P., Porter, Danielle P., Cihlar, Tomas, Baric, Ralph S., Denison, Mark R., Sheahan, Timothy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340027/ https://www.ncbi.nlm.nih.gov/pubmed/32668216 http://dx.doi.org/10.1016/j.celrep.2020.107940 |
Ejemplares similares
-
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
por: Schäfer, Alexandra, et al.
Publicado: (2021) -
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021) -
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021) -
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
por: Feng, Joy Y., et al.
Publicado: (2022) -
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
por: Schäfer, Alexandra, et al.
Publicado: (2022)